1.28
price up icon1.59%   0.02
pre-market  Vorhandelsmarkt:  1.31   0.03   +2.34%
loading
Schlusskurs vom Vortag:
$1.26
Offen:
$1.28
24-Stunden-Volumen:
1.43M
Relative Volume:
0.61
Marktkapitalisierung:
$53.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.69M
KGV:
-0.9209
EPS:
-1.39
Netto-Cashflow:
$-46.54M
1W Leistung:
+44.00%
1M Leistung:
-31.91%
6M Leistung:
-11.11%
1J Leistung:
-18.99%
1-Tages-Spanne:
Value
$1.21
$1.32
1-Wochen-Bereich:
Value
$0.88
$1.32
52-Wochen-Spanne:
Value
$0.6254
$2.75

Milestone Pharmaceuticals Inc Stock (MIST) Company Profile

Name
Firmenname
Milestone Pharmaceuticals Inc
Name
Telefon
(514) 336-0444
Name
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Name
Mitarbeiter
33
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
MIST's Discussions on Twitter

Vergleichen Sie MIST mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MIST
Milestone Pharmaceuticals Inc
1.28 53.89M 0 -59.69M -46.54M -1.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-22 Eingeleitet Rodman & Renshaw Buy
2023-06-20 Herabstufung Jefferies Buy → Hold
2022-04-22 Hochstufung Piper Sandler Neutral → Overweight
2021-03-05 Eingeleitet H.C. Wainwright Buy
2020-07-29 Hochstufung Oppenheimer Perform → Outperform
2020-07-24 Hochstufung Jefferies Hold → Buy
2020-03-25 Herabstufung Jefferies Buy → Hold
2020-03-24 Herabstufung Oppenheimer Outperform → Perform
2020-03-24 Herabstufung Piper Sandler Overweight → Neutral
2019-06-04 Eingeleitet Oppenheimer Outperform
2019-06-03 Eingeleitet Cowen Outperform
2019-06-03 Eingeleitet Jefferies Buy
2019-06-03 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten

pulisher
Apr 23, 2025

Milestone Pharmaceuticals Inc (MIST) looking to reclaim success with recent performance - Sete News

Apr 23, 2025
pulisher
Apr 23, 2025

Market Watch Highlights: Milestone Pharmaceuticals Inc (MIST) Ends on an Upturn Note at 1.06 - DWinneX

Apr 23, 2025
pulisher
Apr 22, 2025

Milestone Pharmaceuticals Inc’s Mixed Bag: Down -30.82% in 6 Months, Down -48.21% in 30 Days - investchronicle.com

Apr 22, 2025
pulisher
Apr 22, 2025

A stock that deserves closer examination: Milestone Pharmaceuticals Inc (MIST) - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Milestone Pharmaceuticals Inc [MIST] Investment Guide: What You Need to Know - knoxdaily.com

Apr 22, 2025
pulisher
Apr 09, 2025

Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT - Seeking Alpha

Apr 09, 2025
pulisher
Apr 05, 2025

Research Analysts Set Expectations for MIST Q1 Earnings - Defense World

Apr 05, 2025
pulisher
Apr 05, 2025

MIST stock touches 52-week low at $0.7 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

MIST stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Cut to Hold at TD Cowen - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India

Apr 01, 2025
pulisher
Mar 31, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Reta - Asianet Newsable

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - NewsBreak: Local News & Alerts

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone flagging following CRL - The Pharma Letter

Mar 28, 2025
pulisher
Mar 28, 2025

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma says FDA declined to approve heart disorder therapy - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - MarketScreener

Mar 28, 2025
pulisher
Mar 27, 2025

Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews

Mar 27, 2025

Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):